Balchem Corp
BCPCWithin bandExpectations · demandingHeld by 2 superinvestors.
SEC 10-K · fundamentals
Business quality
as of 2025-12-31- Revenue growth
- +8.8%
- Net margin
- 14.9%
- ROE
- 12.3%
- FCF margin
- —
Valuation · value band
In fair-value range
Zero-growth floor
$35
Central IV
$38
Optimistic top
$172
Balchem Corp (BCPC): Two methods value the business — a conservative owner-earnings DCF and a growth-credited Greenwald estimate, $35–$172 / sh. Today’s price sits inside both (price $163 as of 2026-07-20).
The middle figure is the main read. The right end is the optimistic case under the same conservative caps — not an absolute ceiling.
Revenue growth 0% (lower of historical trend and fundamental cap, capped by moat) · moat 20 yr · discount 10.5% · Zero-growth downside $35
Price as of 2026-07-20 · yahoo · DGS10 4.5% @ 2026-07-17.
Method & numbers
Model cautions
- The two methods’ midpoints differ materially — growth assumptions warrant review (over 20%).
A conservative intrinsic-value band (zero-growth floor to growth-capped DCF) plus a tangible asset floor — not investment advice, not a buy/sell signal, and not a price target.
Owner-earnings DCF $32.64 – $44.33 · Greenwald $83.10 – $171.61 (neutral $130.69) · zero-growth base $51.42 · reproduction $10.94
Moat Franchise (moat) · terminal value 14% of present value · owner-earnings yield 2% vs 10Y 4.5%.
Graham earnings-power value (normalized NOPAT)$42.49 – $51.42 / sh
Normalized NOPAT = average operating margin over the years shown × latest-year revenue × (1 − normalized tax); then + D&A − maintenance capex (write A). Unlevered (pre-interest, attributable to all capital). Capitalized at the 9–11% rate band (read as a WACC proxy). Enterprise → equity bridge applied: + cash − total debt.
Years: 2025, 2024, 2023, 2022, 2021
v1 simplifications: Maintenance capex unavailable → degraded to the v1 simplification (maintenance capex = D&A, so the depreciation add-back nets to zero). Share-based compensation is left as a real expense (not added back).
Buffett owner-earnings value$35.30 – $43.15 / sh
Owner earnings = average net income + average D&A − maintenance capex (zero-growth floor; no ΔNWC). Levered (starts from net income, already after interest — an equity-holder stream). Capitalized at the 9–11% rate band (read as a cost-of-equity proxy). No enterprise→equity bridge: the capitalized result is already equity value (subtracting debt would double-count interest).
Years: 2025, 2024, 2023, 2022, 2021
v1 simplifications: Maintenance capex or D&A unavailable → degraded to normalized net income (= average net income over the years shown). One-time items are not separately normalized (multi-year averaging smooths them partially). Share-based compensation is left as a real expense (not added back); see the SBC/OE disclosure. Capitalized at the 9–11% band as a cost-of-equity proxy; no leverage premium applied (net cash or debt within the no-charge range).
Reproduction value = tangible net assets $308.04M + capitalized R&D $48.55M（FY 2025, 2024, 2023, 2022, 2021） = $10.94 / sh. Reproduction value = tangible net assets (equity − goodwill − intangibles) + capitalized R&D (5y straight-line), ÷ diluted shares.
Moat reading: Franchise test compares earnings power (EPV) against reproduction value on both AV_conservative (tangible + capitalized R&D) and AV_reproduction (conservative + acquired-reset proxy). Both must clear the franchise multiple for a moat signal; near it, a commodity; below it, value destruction. A directional reading, not a verdict.
Assumes a wide moat · competitive-advantage period ≈ 20 years (earnings intact, ROIC stable over history).
Growth value: if the moat holds for 20 yr at ROIIC ≈ 165%, $31.68–$120.18 / sh (neutral $79.27). Conservative, not a forecast.
Window FY 2025, 2024, 2023, 2022, 2021 · discount band 9%–11% · normalized tax 21% (Average effective tax rate over 5 year(s), capped at the statutory 21%.) · diluted shares.
Owner-earnings DCF: growth g₁ 0% · OE FY 2025, 2024, 2023, 2022, 2021 · Discount band: 9.05%–12.00% (DGS10 +4.5% to a 12% strict end, as of 2026-07-17). No enterprise→equity bridge: owner earnings already flow to shareholders (post-interest), so no net cash is added and no debt subtracted — matching the engine owner-earnings lamp. Two-method midpoint gap 110%.
What the price is betting
Today's price pencils in about 19.2% a year in owner-earnings for the next few years. Revenue actually grew 7.2% a year.
The market wants it well ahead of its own track record.
SEC 13F · holders
Superinvestors Holding This Security
2 holders · $39.0M combined · this quarter +0 opened / -0 exited
- Value$36.1MWeight (prev→now)0.1% → 0.1% ▲
- Value$2.9MWeight (prev→now)0.0% → 0.0% ▲
SEC 13F · notes
Written summary
Written summary
Balchem Corp (BCPC) is held by 2 of the superinvestors tracked on Compounder, with a combined $39.0M in reported 13F value. The largest position belongs to Jeremy Grantham, where it makes up 0.1% of the portfolio.
Other notable holders by value include Ray Dalio (0.0% of its book).
Over the latest quarter, 0 of the tracked filers opened a new position in BCPC, 2 added to existing ones, 0 trimmed, and 0 sold out entirely.
Holder counts and values reflect the most recent SEC Form 13F filings, through the quarter ended 2026-03-31. Source: SEC EDGAR. A 13F shows only long US-listed positions and can lag the real portfolio by up to 45 days, so this is disclosed long ownership, not a complete picture.
SEC 13F · co-ownership
Also held by these investors
Investors holding Balchem Corp (BCPC) also commonly hold →
- Ss Spdr S&P 500 Etf Trust-UsSPY2 holders
- Microsoft CorpMSFT2 holders
- Alphabet Inc-Cl AGOOGL2 holders
- Amazon.Com IncAMZN2 holders
- Johnson & JohnsonJNJ2 holders
- Meta Platforms Inc-Class AMETA2 holders
BCPC's price is not below its conservative value band. See current strike-zone stocks
Sources· SEC EDGAR 13F as of 2026-03-31 · filed 2026-05-15
Educational data only — not investment advice. 13F positions are self-reported and can lag up to 45 days.
Stay Updated
New-quarter 13F moves and valuation updates, to your inbox.